Zum Hauptinhalt springen
Dekorationsartikel gehören nicht zum Leistungsumfang.
Inside the Orphan Drug Revolution
The Promise of Patient-Centered Biotechnology
Buch von James A Geraghty
Sprache: Englisch

37,55 €*

inkl. MwSt.

Versandkostenfrei per Post / DHL

Lieferzeit 1-2 Wochen

Kategorien:
Beschreibung
"There are thousands of diseases classed as "rare" because they afflict only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Forty years ago, a revolution started that transformed the prospects of patients with rare diseases. This book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen, and it tells deeply personal stories of patients and parents willing to risk new, untried therapies"--
"There are thousands of diseases classed as "rare" because they afflict only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Forty years ago, a revolution started that transformed the prospects of patients with rare diseases. This book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen, and it tells deeply personal stories of patients and parents willing to risk new, untried therapies"--
Über den Autor
A widely recognized leader in the rare disease field, Jim Geraghty has been a director or chair of seven NASDAQ-listed biotech companies. He's worked on orphan drugs for more than 40 years--as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. A former trustee of Harvard Medical School's renowned Joslin Diabetes Center, he's spoken before both houses of Congress, at the World Economic Forum, and at many other high-profile conferences. A Georgetown graduate with a masters in psychology from Penn and a law degree from Yale, he is a citizen of three countries and lives in Boston.
Details
Erscheinungsjahr: 2022
Genre: Technik allg.
Rubrik: Naturwissenschaften & Technik
Medium: Buch
Inhalt: Gebunden
ISBN-13: 9781621824688
ISBN-10: 1621824683
Sprache: Englisch
Einband: Gebunden
Autor: Geraghty, James A
Hersteller: Cold Spring Harbor Laboratory Press,U.S.
Maße: 237 x 161 x 25 mm
Von/Mit: James A Geraghty
Erscheinungsdatum: 20.09.2022
Gewicht: 0,67 kg
Artikel-ID: 121314919
Über den Autor
A widely recognized leader in the rare disease field, Jim Geraghty has been a director or chair of seven NASDAQ-listed biotech companies. He's worked on orphan drugs for more than 40 years--as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. A former trustee of Harvard Medical School's renowned Joslin Diabetes Center, he's spoken before both houses of Congress, at the World Economic Forum, and at many other high-profile conferences. A Georgetown graduate with a masters in psychology from Penn and a law degree from Yale, he is a citizen of three countries and lives in Boston.
Details
Erscheinungsjahr: 2022
Genre: Technik allg.
Rubrik: Naturwissenschaften & Technik
Medium: Buch
Inhalt: Gebunden
ISBN-13: 9781621824688
ISBN-10: 1621824683
Sprache: Englisch
Einband: Gebunden
Autor: Geraghty, James A
Hersteller: Cold Spring Harbor Laboratory Press,U.S.
Maße: 237 x 161 x 25 mm
Von/Mit: James A Geraghty
Erscheinungsdatum: 20.09.2022
Gewicht: 0,67 kg
Artikel-ID: 121314919
Warnhinweis

Ähnliche Produkte

Ähnliche Produkte